Skip to main content

Allergic Conjunctivitis Market Size to Surpass USD 4.26 Billion by 2030, exhibiting a CAGR of 5.7%

As per the report by Fortune Business Insights, The Global Allergic Conjunctivitis Market size is projected to reach USD 4.26 Billion by 2030, at a CAGR of 5.7% during the forecast period.

Allergic Conjunctivitis Market

Allergic Conjunctivitis Market (2023-2030)
Allergic Conjunctivitis Market (2023-2030)

Pune, India, Aug. 28, 2023 (GLOBE NEWSWIRE) — The global allergic conjunctivitis market size was USD 2.74 billion in 2022 and it is projected to grow from USD 2.89 billion in 2023 to USD 4.26 billion by 2030, exhibiting a CAGR of 5.7% during the forecast period. Allergic conjunctivitis is a disorder where the eye’s conjunctiva inflates due to an allergic reaction resulting from an individual’s interaction with an allergen.

This disease affects a considerable proportion of the global population but is often underdiagnosed and ignored by the patient and the healthcare professional.

Fortune Business Insights™ mentioned this in a report titled “Allergic Conjunctivitis Market, 2023-2030.”

Key Industry Development:

  • March 2022: Johnson & Johnson Vision Care, Inc. declared the approval of ACUVUE Theravision with Ketotifen by U.S. FDA.


Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/allergic-conjunctivitis-market-100121


Key Takeaways:

  • The FDA in the United States has approved etafilcon, a drug-eluting contact lens containing ketotifen, under the brand name ACUVUE Theravision, according to Johnson & Johnson Vision Care, Inc.
  • Pataday Once Daily Relief Extra Strength is now widely available at retail locations in the United States, according to Alcon.
  • Alaway Preservative Free Antihistamine Eye Drops, the first over-the-counter (OTC) preservative-free formulation eye drop, was introduced by Bausch & Lomb.
  • The first brand-new, prescription-only medication for allergic conjunctivitis in the United States in ten years, ZERVIATE (cetirizine ophthalmic solution) 0.24%, was just released, according to Eyevance Pharmaceuticals LLC.

Discover the Leading Players Featured in the Report:

Major players in the allergic conjunctivitis market are Allergan (AbbVie Inc.) (U.S.), Santen Pharmaceutical Co., Ltd. Japan), Bausch & Lomb Incorporated (Canada), Alcon (Switzerland), Novartis AG (Switzerland), Eyevance Pharmaceuticals LLC (U.S.), Sun Pharmaceutical Industries Ltd. India), Ocular Therapeutix, Inc. (U.S.), Eton Pharmaceutical (U.S.)

Report Scope

Report CoverageDetails
Forecast Period2023 to 2030
Forecast Period 2023 to 2030 CAGR5.7%
2030 Value ProjectionUSD 4.26 Billion
Base Year2022
Market Size in 2023USD 2.89 Billion
Historical Data for2019 to 2021
No. of Pages140


Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/allergic-conjunctivitis-market-100121


Drivers & Restraints:

Rapid Growth in Number of Ocular Allergens to Drive the Market Growth

The occurrence of ocular allergy has increased intensely over the past few decades due to several factors that comprise rapid industrialization and urbanization coupled with the increase in the number of allergens.

A significant lack of understanding about the various symptoms of eye allergies. Hence patients do not visit ophthalmologists regularly unless there is a major or severe symptomatic condition.

Segmentation:

Mast Cell Stabilizers and Antihistamines Segment to Skyrocket the Growth of New Product

Based on drug class, the market is divided into corticosteroids, antihistamines & mast cell stabilizers, and others.

The antihistamines & mast cell stabilizers segment is expected to expand at a significant CAGR over the projected period, owing to their reputation as the gold standard treatment for ocular energy.

Expensive Treatment Costs of Severe Allergic Conjunctivitis to Permit the Segment’s Dominance

On the basis of disease type, the market is bifurcated into mild and severe.

The severe allergic conjunctivitis segment leads with the largest share for multiple reasons. Treating this form of conjunctivitis necessitates, the usage of advanced and strong prescription pharmaceuticals.

Hospital Pharmacies to Dominate Due to High Demand for These Institutions for Medical Examinations

According to the distribution channel, the market is fragmented into drug stores & retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment is expected to accredit for the largest market share during the projected period. The dominance of the segment is due to the increasing demand for institutions with trained medical professionals.

By Drug Class           

  • Antihistamines & Mast Cell Stabilizers
  • Corticosteroids
  • Others

By Disease Type       

  • Mild Allergic Conjunctivitis
  • Severe Allergic Conjunctivitis

By Distribution Channel     

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region     

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


Quick Buy – Allergic Conjunctivitis Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100121

 

Report Coverage:

  • Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
  • Comprehensive insights into regional developments.
  • List of major industry players.
  • Key strategies adopted by the market players.
  • Latest industry developments such as product launches, partnerships, mergers, and acquisitions.  

Regional Insights:

North America to Lead the Market Owing to Surging Occurrence of Ocular Allergies

North America held the largest share in 2022 and is predicted to continue to dominate the global allergic conjunctivitis market share during the projected period. The region’s growth is due to the widespread awareness of ocular allergies, the vital occurrence of this disease, and the presence of key players resulting in the launches of advanced drugs.

Asia Pacific market is anticipated to record the highest CAGR owing to surging awareness, considerable improvements in healthcare expenditure, and a rising occurrence of ocular allergies in the region.

Competitive Landscape:

Healthy Product Portfolio of Prominent Players to Ensure Apex Position

The market is dominant owing to the presence of major players of different sizes, with a number of players targeting the genetic drug space for the treatment of eye allergies. Moreover, companies such as Alembic Pharmaceuticals Limited and Sun Pharmaceuticals are growing their presence in the global market by focusing on product approvals and introducing generic versions of existing drugs.

FAQ’s

How big is the Allergic Conjunctivitis Market?

Allergic Conjunctivitis Market size was USD 2.89 Billion in 2023.

How fast is the Allergic Conjunctivitis Market growing?

The Allergic Conjunctivitis Market will exhibit a CAGR of 5.7% during the forecast period, 2019-2030

Related Reports:

Conjunctivitis Treatment Market Share, Size, Trends and Forecast 2020-2027

Dry Eye Syndrome Market Size, Share, Trends, Growth | Global Forecast Report 2030

Ophthalmic Disease Therapeutics Market Size, Share| Global Forecast Report 2030

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends, Growth | Global Forecast Report 2027

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

Contact Us:

Fortune Business Insights Pvt. Ltd.
9th Floor, Icon Tower, Baner – Mahalunge Road,

Baner, Pune-411045,

Maharashtra, India.

Phone:

US:+1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.